You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Anemia of CKD… The Science Behind the Disease

  • Authors: Jay Wish, MD; Anil K. Agarwal, MD, FASN, FACP, FASDIN
  • CME / ABIM MOC Released: 2/9/2023
  • Valid for credit through: 2/9/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for nephrologists, hematologists/oncologists, primary care practitioners, cardiologists, diabetologists/endocrinologists, and specialty-related nurse practitioners and physician assistants.

The goal of this activity is for learners to be better able to understand the pathophysiology of anemia associated with CKD in order to appreciate the mechanisms of emerging therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Pathophysiology of anemia of CKD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Jay Wish, MD

    Professor of Clinical Medicine
    Indiana University School of Medicine
    Indianapolis, Indiana

    Disclosures

    Jay Wish, MD, has the following relevant financial relationships:
    Consultant or advisor for: Akebia; Amgen Inc. (former); AstraZeneca (former); Behring CSL (former); Disc Medicine (former); FibroGen, Inc. (former); GlaxoSmithKline; Otsuka Pharmaceutical Co., Ltd. (former); Rockwell Medical Inc. (former)
    Speaker or member of speakers bureau for: Akebia; AstraZeneca

  • Anil K. Agarwal, MD, FASN, FACP, FASDIN

    Professor of Nephrology
    University of California San Francisco
    Academy Professor, Ohio State University
    Chief of Medicine
    VA Central California Health Care System
    Fresno, California

    Disclosures

    Anil K. Agarwal, MD, FASN, FACP, FASDIN, has the following relevant financial relationships:
    Consultant or advisor for: Akebia (former)
    Speaker or member of speakers bureau for: AstraZeneca (former)

Editor

  • Iwona Misiuta, PhD, MHA

    Medical Education Director, Medscape, LLC

    Disclosures

    Iwona Misiuta, PhD, MHA, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Anemia of CKD… The Science Behind the Disease

Authors: Jay Wish, MD; Anil K. Agarwal, MD, FASN, FACP, FASDINFaculty and Disclosures

CME / ABIM MOC Released: 2/9/2023

Valid for credit through: 2/9/2024

processing....

 

 

Speaker 1 (00:00): Prior to beginning the activity, please be sure to review the faculty information and disclosure statements as well as the learning objectives. After listening to the activity, complete the post-test by clicking the Earn Credit link. (00:13): In the episode description, downloadable slides and resources are also available. (00:18): The following presentation is copyrighted by Medscape. No use, broadcast, or recording of this presentation or any part thereof is permitted without the written authorization of Medscape. Dr. Jay Wish (00:30): Hello, I'm Dr. Jay Wish, professor of clinical medicine at the Indiana University School of Medicine in Indianapolis, Indiana. Welcome to this program titled Anemia of CKD: The Science Beyond the Disease, part of the Updates and Advances in Anemia of Chronic Kidney Disease Series. Joining me today is Dr. Anil Agarwal, who is professor of medicine at the University of California San Francisco, academy professor at Ohio State University, and chief of medicine at the VA Central California Health System in Fresno, California. Welcome, Anil. Dr. Anil Agarwal (01:06): Glad to be here. Dr. Jay Wish (01:09): Anemia is a common complication of chronic kidney disease or CKD. The prevalence of anemia in patients with CKD increases as the disease progresses and about 50% of all patients with stage 5 CKD have associated anemia. (01:24): This is episode one in the six part podcast series on understanding and managing anemia in patients with CKD. In this episode, we'll focus on the pathophysiology of anemia associated with CKD and dive into why new treatment strategies are needed in managing anemia in these patients. (01:46): Let's start with our first question. Anil, what are the major new things we've learned about the pathophysiology of CKD anemia since recombinant erythropoietin was approved in 1989? Dr. Anil Agarwal (02:00): That's a great question. First of all, thank you, Medscape, and thank you, Dr. Wish, for inviting me to talk about the pathophysiology and the new understanding about pathophysiology in treatment of anemia of CKD. (02:16): As you know, if you recall from the days of medical school decades ago, you'll remember that we only had couple of different factors that we understood what caused anemia, and one was the deficient erythropoietin. As the kidney starts losing nephrons and starts producing less and less erythropoietin, people get become erythropoietin deficient. And once there is erythropoietin deficiency, there is not enough kick to the bone marrow to produce more red cells. The second thing that we understood at the time was the deficiency of iron. As you know, there are multiple reasons. The patients are not eating well, they are nutritionally deficient in general, they lose blood in different ways and there's likelihood of more bleeding and consequently, the patients are iron deficient. And if you recall, for decades, the only things available to treat anemia of chronic kidney disease was essentially just the iron and blood transfusions. (03:24): The biggest discovery, as you mentioned, was really the approval of epoetin back in 1989 for treatment of anemia of CKD, and that changed lives of millions of dialysis patients. Prior to that, intravenous iron and blood transfusion, as you know, were the most effective therapies, but knowing what we know now today, none of these really addressed the real pathophysiology. (03:55): What is new now that we are talking about is we have two very important recent discoveries that have very significantly improved our understanding of anemia of CKD. First, we know now that that inflammation, working through hepcidin, regulates and restricts absorption and availability of iron for erythropoiesis. That is very important because if you just think about a CKD patient on any given day, they have a lot of inflammation going on. Second, we are really thankful to the Nobel Prize-winning discovery of hypoxia-inducible factor that has really afforded to us invaluable insight into the mechanism of how erythropoietin is produced in response to hypoxia, and at the same time, both these discoveries have afforded us opportunity to discover some potential breakthroughs in our knowledge and approach to management of anemia of CKD. Dr. Jay Wish (05:01): So let me pursue this whole issue of inflammation and hepcidin in the anemia of chronic kidney disease. Please explain what their role is and how they affect red cell production. Dr. Anil Agarwal (05:13): All right, that's a great question. Well, let's think about how this even evolved. We recognized inflammation as a contributor to anemia in patients with CKD over decades. We realized that patients are being treated, they're not responding to management, and now they're getting more and more anemic despite proper treatment. But its exact relationship to anemia of CKD remained unclear until the turn of this century. It is very interesting to note that hepcidin was discovered as a liver-expressed antimicrobial peptide or the LEAP peptide, and it is a 25-amino acid peptide that is produced mostly by the hepatocytes in response to inflammation, as well as due to iron overload. It is considered part of native immunity, to restrict supply of iron to microbes which may utilize iron as a micronutrient. Now we know and understand the hepcidin is actually the master regulator of iron absorption and transport. (06:27): How it works then is that hepcidin-25 binds to ferroportin. Ferroportin is a transmembrane protein that is responsible for efflux of iron from the cell. When ferroportin is internalized and degraded, release of iron from enterocytes, from macrophages and hepatocytes, all the cells involved in the turnover of iron and red cells, that is inhibited, which negatively impacts the absorption and availability of iron and also utilization of iron. Finally, hepcidin is cleared via its internalization and degradation with ferroportin as well as through its excretion by the kidneys. So it is no surprise to me that when the patients have lower kidney function, there is a higher level of hepcidin in the blood because they're just simply not able to excrete hepcidin from the system. (07:28): Production of the hepcidin is regulated by the systemic availability of iron in a feedback mechanism and erythropoietic requirement also, because when you want to make red cells, you want to have more iron available and less hepcidin. So a state of inflammation, in other words is a very, very important discovery for us in this era. Dr. Jay Wish (07:54): So it's been shown by some studies that hepcidin levels do increase almost proportionally to the degree of renal function impairment. And the patients with more advanced CKD generally have significant elevations of hepcidin, which is fairly consistent with their level of renal sufficiency. Should we be routinely measuring hepcidin levels in our anemic CKD patients? Dr. Anil Agarwal (08:15): Well, I can understand the reason why that question is being asked and if you think about it, there has been an eternal desire to have a really perfect test of iron deficiency. That, unfortunately, remains a fantasy to this day. As you know, a variety of laboratory tests have been used to assess iron deficiency in patients with anemia, including some of those are ferritin, transferrin saturation, percent of hypochromic red cells, and soluble transferrin receptor. However, all these current methods of assessing adequacy of iron stores and iron availability to the intron are grossly inadequate, especially when you throw in the presence of inflammation into the mix. So these tests are really unable to guide the clinician to formulate a strategy to treat anemia with iron. Association of hepcidin levels with the stage of CKD and ferritin and its inverse relationship with ESA therapy do support the possibility that hepcidin could be a good biomarker of iron status. (09:30): But think about it, there is significant intrapatient variability of hepcidin level measurements. Then, hepcidin is dependent on kidney function for its excretion and for those reasons, the level of hepcidin can simply be high because of kidney insufficiency. Additionally, hepcidin is dependent on kidney function for its excretion and the levels increase with the presence of inflammation and are not necessarily different in patients sensitive or resistant to ESA. When you consider all of these factors, along with the non-harmonization of different hepcidin assays, the hepcidin levels cannot be considered a good biomarker of iron status in their current form, or even a predictor of ESA response, at this time. There are also some biological variations. For example, women have a lower level of hepcidin than men, and there is a diurnal variation, with levels being lower in the morning, higher in the afternoon. Those factors make it even more difficult to how we even interpret hepcidin levels, leave alone how they help us formulating a strategy of iron supplementation. Dr. Jay Wish (10:50): So it sounds like the answer to that question is a no, but what can we do diagnostically and therapeutically to address the role of inflammation in our anemic CKD patients? Dr. Anil Agarwal (11:02): Yes, we have to have some way of addressing the role of inflammation in anemic CKD patients. And first of all, in any patients with anemia, especially who is not being so responsive or a so-called erythropoietin resistance, in those patients, we should have a very high index of suspicion from get-go for inflammation. (11:28): Diagnostically, what you would do is first of all, start with the basics. Do a good physical examination, look for the source of inflammation. Could it be dental caries? Could it be old non-functional abscesses that have been shown to be very inflamed? And we should also look for any other apparent source of inflammation that that might be there. We should remember that the use of non-biocompatible dialysate, both in PD and hemodialysis, those can be source of inflammation in almost any patient. (12:03): There are other reasons why there could be inflammation. Think about heart failure. That has been associated with inflammation in patients with kidney disease. Further, once you have done the examination, the next step would be to do a good laboratory evaluation for functional iron deficiency. You might find an elevated ferritin level with low transferrin saturation. There may be other measures to look for inflammation including checking for high sensitivity CRP or C-reactive protein. Also, erythrocyte sedimentation rate. I know that some of these are very nonspecific, but still those could indicate presence of inflammation. And as I mentioned earlier, hepcidin assay unfortunately does not help us too much in this regard and probably is not ready for prime time. (12:56): Then, approaching inflammation. Now we did the exam, we did the testing, we found inflammation. Therapeutically, what do we do in these patients? (13:07): If you discover a source of inflammation, please treat it promptly and appropriately. Just increasing the dose of iron, increasing the dose of EPO, may not be beneficial and probably have a potential to cause more damage. Unfortunately at this time, there are no specific approved therapies to treat elevated hepcidin, although many molecules have been tried in experimental studies, but those are nowhere close to being in clinical studies yet. Then therapy with hypoxia-inducible factor, that is something that is being tested and has been in vogue quite a bit lately. That has been shown to be effective even in presence of inflammation in treating anemia of CKD in randomized controlled trials. So these agents are currently not approved, let me declare that, disclose that right now that these are not currently approved for treatment of anemia of CKD, at least in the United States. So there are multiple strategies as you can see, but you have to really start from the very basics. Dr. Jay Wish (14:21): Briefly, what is the role of hypoxia-inducible factor, or HIF, in the pathophysiology of CKD anemia? Dr. Anil Agarwal (14:30): So very remarkably, now we have this knowledge of this hypoxia-inducible factor and how it works in the pathophysiology. So the hypoxia-inducible factor is a transcription factor. It is constantly produced by all somatic cells. It has the potential of increasing erythropoietin production, in addition to activation of hundreds of other genes. However, under normal oxygen condition, or under normoxia, HIF is constantly degraded. That occurs through the action of HIF protyl hydroxylase or HIFPHI enzymes. What they do is they add a hydroxyl group to specific proline residues on HIF. This serves as a tag for proteasomal degradation, and that's the end of the story for the HIF. (15:27): But in presence of hypoxia, such as a person is at a high altitude or upon administration of a drug that is a pH antagonist, this protyl hydroxylase enzyme is inactivated that allows for activation of erythropoietin gene transcription. (15:51): Now it is extremely important. We are all aerobic organisms. Elucidation of the detailed mechanism by which cells can sense oxygen allows the development of specific molecules that target specific proteins or processes. It has a potential to treat many diseases, including cancer, stroke, and inflammation, apart from CKD anemia. And no surprise to me, in 2019, doctors Gregg Semenza, William Kaelin, and Peter Ratcliffe were honored with the Nobel Prize in physiology or medicine for their work on deciphering the hypoxia mechanism. Dr. Jay Wish (16:34): I should point out that Dr. Peter Ratcliffe is the only nephrologist ever to have won the Nobel Prize. So we want to make sure that everybody listening to the podcast appreciates that. (16:44): All right, so just last question. How is this discovery of the hypoxia-inducible factor system helpful in our management of anemic patients with CKD? Dr. Anil Agarwal (16:55): So again, just slightly to repeat, the HIF agonist, they block the HIF protyl-hydroxylase enzyme activity. HIF is not degraded but is stabilized. What happens next is once it is stabilized, the HIF-alpha dimerizes with HIF-beta, and the heterodimer then translocates to the nucleus, binds to DNA, coordinates transcription of erythropoietic genes, and there is production of erythropoietin right there. There is also an increase in the number of EPO receptors and these are all further assisted in terms of erythropoiesis by activation of pro-iron absorption genes which allow more streamlined erythropoiesis. Further, the HIF agonists inhibit hepcidin, as demonstrated by their efficacy in improving CKD anemia despite high levels of hepcidin and presence of inflammation demonstrated by high levels of ferritin, low transferrin saturation, and high levels of high sensitivity CRP. Dr. Jay Wish (18:00): Before we conclude, do you have any comments to wrap things up? Dr. Anil Agarwal (18:05): Well, I would just like to summarize that this is a really exciting time in nephrology, and CKD anemia, especially. Now we have a better understanding of pathophysiology of anemia of CKD, and also, it has become very clear to us that the epoetin therapy and iron administration and blood transfusions that we were using for decades do not really address the entire inflammation and hepcidin pathway that usually causes hyporesponse. So it is also quite important to screen and stratify patients with CKD anemia according to presence or absence of adequate iron levels and inflammation to consider potential pathways in treating anemia of CKD. Dr. Jay Wish (18:53): So we now understand that the pathophysiology of anemia of CKD is much more complicated than a simple inability of the diseased kidney to make erythropoietin. It's not analogous to the insulin deficiency of a Type 1 diabetic where you could just replace the insulin and thereby treat the disease. These new insights may provide the foundation for novel therapeutic approaches to anemia in CKD, whose mechanisms of action directly address the pathophysiology we discussed. (19:22): I'd like to thank you for this great discussion, Anil. I really appreciate your sharing your expertise, and I'd also like to thank our audience for participating in this activity. (19:32): Please join us for the remaining five podcasts in this series, Updates and Advances in Anemia of Chronic Kidney Disease. We hope you enjoy the rest of your day. Please continue on to answer the questions that follow and complete the evaluation. We really appreciate your feedback as it helps us develop future educational programs.

  • Print